METHODS OF TREATING CANCER BY INHIBITING UBIQUITIN CONJUGATING ENZYME E2 K (UBE2K)
The disclosure provides methods for the treatment of cancer in a subject comprising administering to the subject an inhibitor of Ubiquitin Conjugating Enzyme E2 K (UBE2K). The UBE2K inhibitor may be administered to the subject as a monotherapy, or in combination with an additional agent, such as an anticancer agent.
1 . A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a Ubiquitin Conjugating Enzyme E2 K (UBE2K) inhibitor, thereby treating the cancer in the subject.
2 . A method of reducing proliferation of a cancer cell in a subject in need thereof, the method comprising administering to the subject a Ubiquitin Conjugating Enzyme E2 K (UBE2K) inhibitor, thereby reducing proliferation of the cancer cell in the subject relative to a subject that is not administered the UBE2K inhibitor.
3 . A method of inducing death of a cancer cell in a subject in need thereof, the method comprising administering to the subject a Ubiquitin Conjugating Enzyme E2 K (UBE2K) inhibitor, thereby inducing death of the cancer cell in the subject.
4 . The method of claim 3 , wherein the death of the cancer cell is induced by apoptosis.
5 . The method of any one of claims 1 - 4 , wherein the UBE2K inhibitor is a specific inhibitor of UBE2K.
6 . The method of any one of claims 1 - 5 , wherein the UBE2K inhibitor comprises a small molecule.
7 . The method of any one of claims 1 - 5 , wherein the UBE2K inhibitor comprises a nucleic acid inhibitor.
8 . The method of claim 7 , wherein the nucleic acid inhibitor comprises an antisense nucleic acid molecule.
9 . The method of claim 7 , wherein the nucleic acid inhibitor comprises a double stranded nucleic acid molecule.
10 . The method of claim 9 , wherein the double stranded nucleic acid molecule comprises a double stranded RNA selected from the group consisting of an siRNA, a shRNA, and a dicer substrate siRNA (DsiRNA).
11 . The method of any one of claims 1 - 5 , wherein the UBE2K inhibitor comprises an antibody.
12 . The method of any one of claims 1 - 11 , wherein the cancer comprises a solid tumor.
13 . The method of claim 12 , wherein the solid tumor is selected from the group consisting of carcinoma, melanoma, sarcoma, and lymphoma.
14 . The method of claim 12 , wherein the solid tumor is selected from the group consisting of pancreatic cancer, liver cancer, colorectal cancer, and lymphoma.
15 . The method of claim 12 , wherein the solid tumor is pancreatic cancer or liver cancer.
16 . The method of any one of claims 1 - 11 , wherein the cancer is a leukemia.
17 . The method of any of claims 1 - 16 , wherein the UBE2K inhibitor is administered with an additional agent.
18 . The method of claim 17 , wherein the additional agent is an anti-cancer agent.
19 . The method of claim 17 , wherein the additional agent is a chemotherapeutic agent.
20 . The method of claim 19 , wherein the chemotherapeutic agent is selected from the group consisting of gemcitabine, 5-fluorouracil, leucovorin, docetaxel, fludarabine, cytarabine, cyclophosphamide, paclitaxel, docetaxel, busulfan, methotrexate, daunorubicin, doxorubicin, melphalan, cladribine, vincristine, vinblastine, chlorambucil, tamoxifen, taxol, camptothecin, actinomycin-D, mitomycin C, combretastatin, cisplatin, etoposide, verapamil, podophyllotoxin, and 5-fluorouracil.
21 . The method of claim 17 , wherein the additional agent is an anti-angiogenic agent.
22 . The method of claim 17 , wherein the additional agent is an immunotherapeutic.
23 . The method of claim 22 , wherein the immunotherapeutic is an immune checkpoint modulator of an immune checkpoint molecule.
24 . The method of 23, wherein the immune checkpoint molecule is selected from CD27, CD28, CD40, CD122, OX40, GITR, ICOS, 4-1BB, ADORA2A, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG-3, PD-1, PD-L1, PD-L2, TIM-3, and VISTA.
25 . The method of claim 23 , wherein the immune checkpoint molecule is a stimulatory immune checkpoint molecule and the immune checkpoint modulator is an agonist of the stimulatory immune checkpoint molecule.
26 . The method of claim 23 , wherein the immune checkpoint molecule is an inhibitory immune checkpoint molecule and the immune checkpoint modulator is an antagonist of the inhibitory immune checkpoint molecule.
27 . The method of any one of claims 23 - 26 , wherein the immune checkpoint modulator is selected from a small molecule, an inhibitory RNA, an antisense molecule, and an immune checkpoint molecule binding protein.
28 . The method of claim 23 , wherein the immune checkpoint molecule is PD-1 and the immune checkpoint modulator is a PD-1 inhibitor.
29 . The method of claim 28 , wherein the PD-1 inhibitor is selected from pembrolizumab, nivolumab, pidilizumab, SHR-1210, MEDI0680R01, BBg-A317, TSR-042, REGN2810 and PF-06801591.
30 . The method of claim 23 , wherein the immune checkpoint molecule is PD-L1 and the immune checkpoint modulator is a PD-L1 inhibitor.
31 . The method of claim 30 , wherein the PD-L1 inhibitor is selected from durvalumab, atezolizumab, avelumab, MDX-1105, AMP-224 and LY3300054.
32 . The method of claim 23 , wherein the immune checkpoint molecule is CTLA-4 and the immune checkpoint modulator is a CTLA-4 inhibitor.
33 . The method of claim 32 , wherein the CTLA-4 inhibitor is selected from ipilimumab, tremelimumab, JMW-3B3 and AGEN1884.